Business Description
Mira Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US60458C1045
Total Employee Number:
2Description
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.99 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -3.7 | |||||
3-Year EPS without NRI Growth Rate | -50.2 | |||||
3-Year FCF Growth Rate | 14.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.74 | |||||
9-Day RSI | 57.8 | |||||
14-Day RSI | 53.4 | |||||
3-1 Month Momentum % | -7.32 | |||||
6-1 Month Momentum % | -33.63 | |||||
12-1 Month Momentum % | -47.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 81.98 | |||||
Quick Ratio | 81.98 | |||||
Cash Ratio | 81.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -41.7 | |||||
Shareholder Yield % | -17.36 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -168.23 | |||||
ROA % | -161.02 | |||||
ROIC % | -15741.16 | |||||
3-Year ROIIC % | 468.71 | |||||
ROC (Joel Greenblatt) % | -18473.58 | |||||
ROCE % | -167.92 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.3 | |||||
PB Ratio | 4.32 | |||||
Price-to-Tangible-Book | 4.37 | |||||
EV-to-EBIT | -3.16 | |||||
EV-to-EBITDA | -3.16 | |||||
EV-to-FCF | -7.31 | |||||
| Price-to-Net-Current-Asset-Value | 4.37 | |||||
| Price-to-Net-Cash | 4.37 | |||||
Earnings Yield (Greenblatt) % | -31.65 | |||||
FCF Yield % | -10.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mira Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.231 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 61.91 | ||
| 14-Day RSI | 53.4 | ||
| 14-Day ATR (€) | 0.038436 | ||
| 20-Day SMA (€) | 0.808975 | ||
| 12-1 Month Momentum % | -47.91 | ||
| 52-Week Range (€) | 0.7675 - 2 | ||
| Shares Outstanding (Mil) | 42.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mira Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mira Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 118 days | ||
| General meeting for 2025 | 2026-09-11 10:00 | In 56 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 27 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.82 (-3.37%) | ||
| Annual report for 2025 | 2026-03-31 | 0.83 (-5.14%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 1.22 (+0.00%) | ||
| General meeting for 2024 | 2025-09-11 10:00 | 1.18 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.23 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 1.04 (-2.80%) | ||
| Annual report for 2024 | 2025-03-28 | 1.07 (+0.00%) |
Show
Entries
Mira Pharmaceuticals Inc Frequently Asked Questions
What is Mira Pharmaceuticals Inc(STU:K6S)'s stock price today?
The current price of STU:K6S is €0.83. The 52 week high of STU:K6S is €2.00 and 52 week low is €0.77.
When is next earnings date of Mira Pharmaceuticals Inc(STU:K6S)?
The next earnings date of Mira Pharmaceuticals Inc(STU:K6S) is 2026-08-14 Est..
Does Mira Pharmaceuticals Inc(STU:K6S) pay dividends? If so, how much?
Mira Pharmaceuticals Inc(STU:K6S) does not pay dividend.
Press Release
Articles on Mira Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers